Public Sector Pension Investment Board Takes Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Public Sector Pension Investment Board bought a new position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 494,500 shares of the biotechnology company’s stock, valued at approximately $9,885,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Hollencrest Capital Management acquired a new stake in ADMA Biologics during the third quarter worth approximately $30,000. Larson Financial Group LLC acquired a new stake in ADMA Biologics during the 3rd quarter worth approximately $31,000. Quest Partners LLC bought a new stake in ADMA Biologics in the 2nd quarter valued at $29,000. Harvest Fund Management Co. Ltd acquired a new position in ADMA Biologics in the 3rd quarter valued at $62,000. Finally, USA Financial Formulas grew its holdings in ADMA Biologics by 8.6% in the 3rd quarter. USA Financial Formulas now owns 6,817 shares of the biotechnology company’s stock valued at $136,000 after buying an additional 539 shares in the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.

Insider Activity at ADMA Biologics

In other news, Director Lawrence P. Guiheen sold 9,000 shares of the stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $18.47, for a total value of $166,230.00. Following the completion of the transaction, the director now owns 153,941 shares of the company’s stock, valued at approximately $2,843,290.27. This represents a 5.52 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Brad L. Tade sold 15,000 shares of ADMA Biologics stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $21.15, for a total transaction of $317,250.00. Following the sale, the chief financial officer now directly owns 199,433 shares in the company, valued at $4,218,007.95. This trade represents a 7.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 3.70% of the stock is currently owned by insiders.

ADMA Biologics Stock Performance

ADMA opened at $21.83 on Friday. The firm has a market cap of $5.16 billion, a P/E ratio of 77.96 and a beta of 0.64. The business’s fifty day moving average is $19.08 and its 200-day moving average is $15.23. ADMA Biologics, Inc. has a 52-week low of $3.60 and a 52-week high of $23.64. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.13 by $0.02. The firm had revenue of $119.84 million for the quarter, compared to the consensus estimate of $107.25 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. During the same period in the prior year, the company posted $0.01 earnings per share. Sell-side analysts expect that ADMA Biologics, Inc. will post 0.52 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on ADMA. Raymond James boosted their target price on shares of ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a research report on Friday, November 8th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $20.00 price objective on shares of ADMA Biologics in a research note on Friday, September 20th. Finally, HC Wainwright increased their target price on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, November 8th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.